Advance and opportunities in nanoparticle drug delivery for central nervous system disorders: A review of current advances
Department of Pharmaceutics, Shri Swami Samarth Institute of Pharmacy, At Parsodi, Dhamangoan Rly, Dist -Amravati (444709) Maharashtra, India.
Review Article
GSC Biological and Pharmaceutical Sciences, 2024, 27(03), 044–058.
Article DOI: 10.30574/gscbps.2024.27.3.0222
Publication history:
Received on 25 April 2024; revised on 02 June 2024; accepted on 05 June 2024
Abstract:
Nanoparticles drug delivery systems have emerged as a cutting-edge approach in treating central nervous system disorders. This review discusses the advancements and opportunities in utilizing nanoparticles for targeted drug delivery to the brain, focusing on their potential to enhance efficacy, reduce side effects, and improve patient outcomes. Lipid-based nanocarriers like liposomes, solid lipid nanoparticles (SLNs) and micelles are widely used in neurological conditions. The growing demand for innovative drug delivery methods for treating neurodegenerative disorders, such as Parkinson's and Alzheimer’s are largely due to potential therapy failures in the blood brain barrier and P-glycoproteins which cause progressive loss of brain function. Nanotechnology advancements can help overcome these limitations by improving the delivery of active medicine campaigns and creating nanomaterials that improve active drug delivery.
Keywords:
Alzheimer's disease (AD); Parkinson's disease (PD); Central nervous system (CNS); Blood brain barrier; Nanotechnolog
Full text article in PDF:
Copyright information:
Copyright © 2024 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0
